Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: An open-label, randomized, two-period crossover comparison in healthy mexican volunteers

Clinical Therapeutics

Volumn 31, Issue 8, 2009, Pages 1796-1803

  Galan Herrera, Juan Francisco ^a   Poo, Jorge Luis ^a   Rosales Sanchez, Oscar ^a   Fuentes Fuentes, Elvira ^a   Cariño, Lizbeth ^b   Burke Fraga, Victoria ^b   Namur, Salvador ^b   Parra, Mario González de la ^b  

^a LIVER RESEARCH UNIT   (Mexico)

^b Fundacion Liomont AC   (Mexico)

Author keywords

bioavailability; bioequivalence; HPTLC; human; levofloxacin; pharmacokinetic

Indexed keywords

EVOCS III; LEVOFLOXACIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DENSITOMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, THIN LAYER; CROSS-OVER STUDIES; DENSITOMETRY; FEMALE; HUMANS; MALE; MEXICO; OFLOXACIN; TABLETS; THERAPEUTIC EQUIVALENCY; TIME FACTORS; YOUNG ADULT;

EID: 72449162141     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.08.004     Document Type: Article

References (15)

1. Fu K.P., Lafredo S.C., Foleno B., et al. In vitro and in vivo antibacterial activities of levofloxacin (L-ofloxacin), an optically active ofloxacin [published correction appears in Antimicrob Agents Chemother. 1992;36:1797]. Antimicrob Agents Chemother 36 (1992) 860-866
2. Consejo de Salubridad General. Novena actualización de la Edición 2006 del Cuadro Basico y Catálogo de Medica-mentos. Diario Oficial (February 18, 2008) 53-58. http://vlex.com.mx/vid/novena-edicion-cuadro-medicamentos-35835956 Accessed July 10, 2009
3. Chien S.C., Rogge M.C., Gisclon L.G., et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother. 41 (1997) 2256-2260
4. Fish D.N., and Chow A.T. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 32 (1997) 101-119
5. Comisión Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS). Relación de Medica-mentos de Referencia (September 2008). http://cofepris.salud.gob.mx/pyp/gi/pdf/Innovadores%20GI.pdf Accessed July 10, 2009
6. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects (WMA). Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland (October 2000). http://www.wma.net/e/policy/b3.htm Accessed February 13, 2009
7. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization (EMEA, and WHO). ICH Topic E6 (R1): Guideline for Good Clinical Practice. http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf Accessed February 13, 2009
8. General Directorate of Standards. Mexican Official Standard NOM177-SSA1-1998. Test and procedures to prove that a medication is interchangeable [in Spanish]. Requirement 8.4. Mexico City, Mexico (1999). http://www.salud.gob.mx/unidades/cdi/nom/177ssa18.html Accessed July 10, 2009
9. Namur S., Cariño L., and González-de la Parra M. Development and validation of a densitometric HPTLC method for quantitative analysis of levofloxacin in human plasma. J Planar Chromato-graphyModern TLC. 21 (2008) 209-212
10. The United States Pharmacopoeial Convention. Levofloxacin monograph, version 2. http://www.usp.org/pdf/EN/pendingStandards/levofloxacin.pdf Accessed February 13, 2009
11. Chow S.C., and Liu J.P. Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd ed. (2000), Marcel Dekker, New York, NY 1-30
12. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (FDA, and CDER). Guidance for Industry: Statistical approaches to establishing bioequivalence. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/ucm070244.pdf Accessed February 13, 2009
13. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 15 (1987) 657-680
14. Tavanic [prescribing information]. Diccionario de Especialidades Farma-ceuticas [in Spanish]. 54th ed. (2008), Thomson PLM, Mexico City, Mexico 3645-3648
15. Lee L.J., Hafkin B., Lee I.D., et al. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. Antimicrob Agents Chemother. 41 (1997) 2196-2200